Pharma Leaders

FDA Approves GE HealthCare’s Flyrcado for Diagnosing Coronary Artery Disease

2 months ago
by David Miller
949 Views

Flyrcado is the first positron emission tomography myocardial perfusion imaging agent of its kind designed for the detection of coronary artery disease.

Flyrcado is the first positron emission tomography myocardial perfusion imaging agent of its kind designed for the detection of coronary artery disease.

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]